Form 4: Amylyx Co-CEO Sells Shares for Tax Obligations

Amylyx Pharmaceuticals' Co-Chief Executive Officer, Joshua B. Cohen, sold 29,282 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Joshua B. Cohen, Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc., reported a sale of company common stock.
• A total of 29,282 shares were sold on March 2, 2026.
• The shares were sold at a weighted average price of $14.484, with individual transaction prices ranging from $14.450 to $15.160.
• The sale was automatic and not at the discretion of Mr. Cohen, executed solely to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Cohen beneficially owns 3,334,683 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's a sale by an insider, it's non-discretionary and for tax purposes, often pre-arranged, which mitigates concerns about management's confidence.

Positives

• The sale was automatic and non-discretionary, solely for tax withholding purposes, indicating it is not a discretionary move by management to reduce exposure.
• The transaction was executed under a Rule 10b5-1(c) plan, which demonstrates pre-planning and adherence to insider trading regulations.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, slightly decreases their direct stake in the company.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider sales for tax withholding purposes, especially when conducted under a Rule 10b5-1 plan, are common in the biotechnology and pharmaceutical sectors as a standard part of executive compensation and do not typically signal a change in management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the non-discretionary nature for tax purposes suggests no change in management's long-term view.
• Employees: No direct impact on employees beyond the executive involved.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale by an executive to cover tax obligations from vested restricted stock units, executed under a 10b5-1 plan. This type of insider activity is generally not indicative of a change in the company's fundamental outlook or management's confidence, and therefore does not warrant a change in investment recommendation based solely on this filing.

Keywords

Amylyx Pharmaceuticals, AMLX, Joshua B. Cohen, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, 10b5-1 Plan, Executive Compensation